# CaRe (NCT06056791)

> Study of INKmune in Patients With mCRPC (CaRe Prostate)

No report yet. It can be ordered.

- Drugs tested: INKmune
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06056791
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Inmune Bio, Inc.
- Conditions: Cancer; Metastatic Castration-resistant Prostate Cancer; mCRPC
- Interventions: INKmune
- Enrollment: 12
- Primary outcome: Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
- Primary outcome: Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
- Primary outcome: Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
- Primary outcome: Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
- Primary outcome: Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
- Primary outcome: Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
- Primary outcome: Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
- Primary outcome: Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.

## Indexed commentary on CaRe so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 4
- Podcasts: 3
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=care-nct06056791

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06056791", "email": "<work email>"}; the inbox owner confirms by the emailed link.